An mRNA cancer immunotherapy from BioNTech has hit a setback in a late-stage trial. According to BioNTech’s statement of 13 October 2026, the Phase 2/3 AHEAD-MERIT study of BNT113 plus pembrolizumab did not show a statistically significant improvement in progression-free survival over pembrolizumab alone in HPV16-positive head and neck cancer.
The independent data monitoring committee recommended that the trial continue to the overall survival analysis, which could still produce a positive result under the study design.
The statement contains no efficacy or safety numbers. This report looks at what the result means for BioNTech’s programme and how far it should colour views of the wider field.
mRNA cancer immunotherapy: key takeaways
- BNT113 is an investigational mRNA cancer immunotherapy that encodes the HPV16 proteins E6 and E7.
- The progression-free survival comparison was not statistically significant. Overall survival is still being assessed.
- BNT113 has FDA Fast Track status from January 2026 but no approval anywhere.
- Enrolment, hazard ratios, response rates, safety data and the survival timeline were not disclosed.
What happened in the mRNA cancer immunotherapy trial AHEAD-MERIT
AHEAD-MERIT (NCT04534205, see the trial registry entry) compares BNT113 plus pembrolizumab with pembrolizumab alone as first-line treatment for unresectable recurrent or metastatic head and neck squamous cell carcinoma that is HPV16-positive and PD-L1 positive with a combined positive score of at least 1. Part B is randomised and has two primary endpoints: progression-free survival and overall survival.
At the progression-free survival analysis, the combination did not do significantly better than pembrolizumab alone. The monitoring committee did not recommend stopping, and instead advised continuing to assess overall survival. BioNTech says it remains blinded to the ongoing data under the trial’s governance procedures, so the company has not seen the detailed results either.
What BioNTech and its leadership said
Prof. Özlem Türeci, BioNTech’s Co-Founder and Chief Medical Officer, said the data support continued evaluation of BNT113 plus pembrolizumab in this trial, and that overall survival will be critical to fully assess the approach’s potential. The company also noted that there are currently no approved HPV-targeted treatments. The statement does not announce any change in development plans or regulatory filings, and no date was given for the survival read-out.
Why one result does not define mRNA cancer immunotherapy
It is tempting to read a late-stage miss as a verdict on the whole technology. That would go too far. mRNA cancer immunotherapy is a category, not a single drug: products differ in the antigens they encode, the cancers they target, the doses and schedules, and the drugs they are combined with.
BNT113 targets two viral proteins in a specific virus-driven cancer and is tested on top of a strong checkpoint inhibitor. A result in that setting says little about products aimed at other antigens or tumours.
At the same time, the result is a reminder that adding an immune-priming therapy to a checkpoint inhibitor is a demanding test. The control arm already uses an effective immunotherapy, so the add-on must show a benefit beyond it. Whether BNT113 can show that on survival is the open question.
What a positive survival result would need
For the study to count as positive on overall survival, the difference between the two arms must reach statistical significance under the pre-specified analysis plan. The size of the benefit matters too: regulators and doctors look at how many months of life are gained, how the curves separate over time, and what side effects patients experience. None of those measures has been disclosed, and a statistically significant result with a small benefit would be received very differently from a large one.
What the mRNA cancer immunotherapy result means for BioNTech
The statement concerns one programme and says nothing about BioNTech’s wider pipeline, finances or other trials. We have not seen analyst or company commentary on the effect on the business, and we do not speculate on it.
What the statement does show is that the company chose to disclose a negative first endpoint openly while the trial remains unresolved, which is the cautious and transparent course for a study that is still running.
For related coverage of how trials are structured and reported, see our report on the ontunisertib Phase 2b trial and more in pharmaceuticals.
The disease behind the trial
According to BioNTech, about one-third of head and neck squamous cell carcinomas are associated with HPV, and most of those with HPV16. The National Cancer Institute provides background on how HPV relates to these cancers. Treatment options for recurrent or metastatic disease are limited, which is why new approaches are being tested, but the release gives no estimate of how many patients might eventually be eligible for BNT113.
What patients should know
BNT113 is not available outside clinical trials, and nothing in the statement changes how approved treatments are used. People with head and neck cancer should continue to follow their oncologist’s advice, and trial participants should ask their study team what the update means for them.
Risks and caveats on mRNA cancer immunotherapy results
- Only a company statement is available. No data have been peer reviewed or presented at a meeting.
- A missed primary endpoint lowers confidence, whatever the survival result.
- The survival analysis has no announced date.
- The result applies to one product in one disease and should not be generalised.
In our assessment, the most useful stance is patience. The trial is not a failure until the survival data are in, and it is not a success because the study continues. The full data set, including safety, will matter more than the headline.
What to watch next for mRNA cancer immunotherapy
- The overall survival analysis for AHEAD-MERIT.
- Full presentation of the progression-free survival data.
- Any update to BNT113 development plans.
- Further disclosures in BioNTech’s regular reporting.
Frequently asked questions
What is mRNA cancer immunotherapy?
A treatment that uses messenger RNA to instruct the body to make proteins that help the immune system recognise tumour cells. BNT113 encodes HPV16 E6 and E7.
Did BioNTech’s BNT113 trial fail?
It missed the progression-free survival endpoint. Overall survival is still being assessed, so the final outcome is unresolved.
Is BNT113 approved?
No. It is investigational and has FDA Fast Track designation.
When will the survival results come?
BioNTech has not given a date.
How we reported this: we relied on BioNTech’s statement of 13 October 2026, the trial registry entry, and the websites of the bodies named. Last updated: 15 October 2026. This article is news reporting and not medical or investment advice.
